+
SMS Pharma Gets EIR for Hyderabad API Facility
ECONOMY & POLICY

SMS Pharma Gets EIR for Hyderabad API Facility

SMS Pharmaceuticals Limited announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility at Bachupally, Hyderabad. The inspection was conducted between 17th and 21st March 2025.

The inspection concluded with one procedural observation on Form 483, which has already been addressed by the company. The issuance of the EIR marks the formal closure of the audit.

The Hyderabad unit has a manufacturing capacity of 120 kilolitres and specialises in niche, small-volume, high-value molecules. It holds multiple global regulatory approvals including those from USFDA, European Union Good Manufacturing Practice (EU GMP), Korea Food and Drug Administration (KFDA), Brazilian Health Regulatory Agency (ANVISA), Pharmaceuticals and Medical Devices Agency (PMDA), and Central Drugs Standard Control Organisation (CDSCO).

Established in 1990, SMS Pharma serves global clients across over seventy countries, with facilities in Hyderabad and Vizag. The company is supported by in-house research and development capabilities and operates in a wide range of therapeutic categories.

Source:
SMS Pharmaceuticals Limited 

SMS Pharmaceuticals Limited announced the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility at Bachupally, Hyderabad. The inspection was conducted between 17th and 21st March 2025. The inspection concluded with one procedural observation on Form 483, which has already been addressed by the company. The issuance of the EIR marks the formal closure of the audit. The Hyderabad unit has a manufacturing capacity of 120 kilolitres and specialises in niche, small-volume, high-value molecules. It holds multiple global regulatory approvals including those from USFDA, European Union Good Manufacturing Practice (EU GMP), Korea Food and Drug Administration (KFDA), Brazilian Health Regulatory Agency (ANVISA), Pharmaceuticals and Medical Devices Agency (PMDA), and Central Drugs Standard Control Organisation (CDSCO). Established in 1990, SMS Pharma serves global clients across over seventy countries, with facilities in Hyderabad and Vizag. The company is supported by in-house research and development capabilities and operates in a wide range of therapeutic categories. Source: SMS Pharmaceuticals Limited 

Next Story
Real Estate

Rs 24.4 Trillion Worth Of Plots Launched Since 2022

Housing plots worth Rs 24.4 trillion have been launched across India’s top tier-I and tier-II cities between January 2022 and May 2025, driven by post-Covid demand for customisable living spaces, according to data from real estate analytics firm PropEquity.During this period, developers rolled out approximately 470,000 residential plots across ten cities—Hyderabad, Indore, Bengaluru, Chennai, Nagpur, Jaipur, Coimbatore, Mysore, Raipur, and Surat.Samir Jasuja, Founder and CEO of PropEquity, stated that the increasing popularity of residential plots stems from their liquidity and stronger ap..

Next Story
Infrastructure Urban

Wyndham, Cygnett To Add 60 Hotels Across South Asia

Wyndham Hotels & Resorts has entered into a strategic alliance with Indian hospitality group Cygnett Hotels & Resorts to significantly expand its presence across South Asia. The collaboration will bring Wyndham’s La Quinta and Registry Collection Hotels brands to India, with plans to develop over 60 hotels across India, Bangladesh, Sri Lanka, and Nepal in the next ten years.This move seeks to capitalise on the growth of India’s travel and tourism industry, fuelled by infrastructure investments, a growing middle class, and rising domestic and international tourism.Dimitris M..

Next Story
Infrastructure Urban

Marengo Asia To Invest Rs 1.5 Billion In West India Expansion

Marengo Asia Healthcare, a prominent multi-specialty hospital platform backed by marquee investors including Samara Capital, Havells Family Office, and the Godrej Family Office, has announced a strategic investment of Rs 1.5 billion to expand its presence into Maharashtra and Rajasthan. The move is part of the group’s wider vision to build a pan-India network by strengthening its operations across northern and western India.Currently operating around 1,500 beds across four hospitals in Delhi NCR and Gujarat, Marengo plans to double its bed capacity to 3,000 within the next 12 months. This wi..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?